Moss Genomics Inc. (MOSS.CN)
| Previous Close | 0.0300 |
| Open | 0.0000 |
| Bid | 0.0200 x N/A |
| Ask | 0.1200 x N/A |
| Day's Range | 0.0300 - 0.0300 |
| 52 Week Range | 0.0100 - 0.1950 |
| Volume | |
| Avg. Volume | 119 |
| Market Cap | 1.345M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
NewsfileMoss to Launch Revolutionary 90-Second Urine Test and Smartphone App
Vancouver, British Columbia--(Newsfile Corp. - September 19, 2023) - Moss Genomics Inc. (CSE: MOSS) ("Moss" or the "Company"), an innovator in the health technology industry, is thrilled to announce that it expects to launch its groundbreaking 90-second urine test and accompanying smartphone app in December 2023. This revolutionary product is set to transform the way individuals monitor their health and detect potential medical conditions, offering quick, accurate, and convenient results at thei
NewsfileMoss Introduces Diet and Vitamin Reports
Vancouver, British Columbia--(Newsfile Corp. - June 16, 2023) - Moss Genomics Inc. (CSE: MOSS) ("Moss" or the "Company"), a consumer genomics and gut microbiome company based in Vancouver, British Columbia announces the introduction of its diet and vitamin reports (the "Reports") which can be ordered directly to your home via our online platform.Up to 80 million genetic variants are analyzed to provide the most insightful information concerning dietary needs and vitamin deficiencies. Our diet ..
NewsfileMoss Genomics and Proteic Bioscience Sign Memorandum of Understanding
Vancouver, British Columbia--(Newsfile Corp. - May 15, 2023) - Moss Genomics Inc. (CSE: MOSS) ("Moss" or the "Company"), a consumer genomics and gut microbiome company based in Vancouver, British Columbia, announces signing of a memorandum of understanding ("MOU") with Proteic Bioscience Inc. ("Proteic"). The MOU outlines an essential understanding of a proposed collaboration between Moss and Proteic to design a suite of new protein structures for the development of commercial supplements intend
